This is consistent with the most recently proposed “very low-risk” endometrial cancer (G1/G2 grade, endometrioid type, MMR-proficient, p53 wild-type, stage IA, no LVSI) in whom POLE testing will not impact on patient care [62,63]. Here, MRC1 is linked to endometrial cancer.